SCHEMBL4944173

SCHEMBL4944173

CC(C)C(=O)N(CCc1ccc(C(=O)O)cc1)NCCC(O)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 12/20 0.51
PTGER2 P43116 5/20 0.51
TBXA2R P21731 1/20 0.43
CYP3A4 P08684 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
USP2 O75604 2/20 0.42
NR1I2 O75469 1/20 0.42
ADRB1 P08588 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
CHRM3 P20309 1/20 0.42
SLC6A2 P23975 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5982073 0.93 PTGER4 (0.51) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL4940816 0.91 PTGER4 (0.53) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL4937190 0.89 PTGER4 (0.51) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL5990886 0.84 PTGER4 (0.53) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL4937202 0.83 PTGER4 (0.54) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL5982721 0.82 PTGER4 (0.51) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL13992256 0.81 PTGER4 (0.59) PTGER4PTGER2TBXA2RCYP3A4CYP1A2
SCHEMBL5616680 0.81 CYP3A4 (0.43) PTGER4PTGER2CYP3A4CYP1A2CYP2D6
SCHEMBL4943296 0.79 PTGER4 (0.51) PTGER4PTGER2TBXA2ROPRM1NR4A2
SCHEMBL4945210 0.78 PTGER4 (0.53) PTGER4PTGER2TBXA2RCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465755-B2 Hydrazide derivatives as prostaglandin receptors modulators LABORATOIRES SERONO SA (CH) 2008-12-16 US claimed
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US claimed
US-7465755-B2 Hydrazide derivatives as prostaglandin receptors modulators LABORATOIRES SERONO SA (CH) 2008-12-16 US disclosed
US-7465755-B2 Hydrazide derivatives as prostaglandin receptors modulators LABORATOIRES SERONO SA (CH) 2008-12-16 US disclosed
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US disclosed
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US disclosed
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US disclosed
EP-1654219-A2 HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2006-05-10 EP disclosed
WO-2005012232-A2 HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185191-A1 Hydrazide derivatives as prostaglandin receptors modulators PTGIR, HPGDS, PGF PTGER4 18/4885PTGER2 13/4885TBXA2R 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.